Risk factor
Very high price volatility
Profitability factor
Favourable analyst view
About
Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candidate for the treatment of duchenne...
Company Valuation
From both historical and forecast perspectives, the stock is overpriced compared to similar stocks. Specifically, the stock is overvalued on EV/EBITDA.
Target Price
The average target price of SLDB is 15 and suggests 148% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increas
Buy
Sell